Optellum Competitive Intelligence & Landscape

Optellum (optellum.com) is a pioneering lung health company specializing in AI-powered decision-support software designed to assist physicians in the early diagnosis and optimal treatment of lung disease, particularly lung cancer. The company's core mission is to ensure that every patient with lung disease is diagnosed and treated at the earliest possible stage, significantly improving health outcomes [https://optellum.com/wp-content/uploads/2024/03/Optellum-Media-Pack-2024-1.0-3-FINAL.pdf]. Their commitment lies in giving lung cancer patients the best chance to fight back against the disease [https://optellum.com/wp-content/uploads/2022/11/Data-team-job-ad-proposal_3.pdf].

Optellum is recognized as a leader in AI-enabled lung cancer diagnosis. Their flagship product, the Optellum® Virtual Nodule Clinic, manages incidental pulmonary nodules, addressing the critical issue that a large percentage of patients with these nodules are not contacted, diagnosed, or treated [https://optellum.com/incidental-management/]. This software helps increase the identification of incidental lung nodule patients and streamlines their care pathway [https://optellum.com/incidental-management/]. The company has achieved significant regulatory milestones, including FDA 510(k) clearance, CE-marking, and UKCA certification for its Virtual Nodule Clinic software, underscoring its commitment to high standards in medical technology [https://optellum.com/wp-content/uploads/2024/03/Optellum-Media-Pack-2024-1.0-3-FINAL.pdf][https://optellum.com/2022/06/optellums-uk-regulatory-certification-bolstered-by-ukca-marking/].

The target market for Optellum includes healthcare providers and institutions focused on lung health and cancer care. For example, Vanderbilt Lung Institute became the first hospital in Tennessee to implement the Optellum Virtual Lung Nodule Clinic [https://optellum.com/2022/01/vanderbilt-lung-institute-implements-optellum-virtual-lung-nodule-clinic/].

Optellum frequently collaborates with industry giants such as GE Healthcare to advance AI-powered lung cancer diagnosis [https://optellum.com/2021/12/ge-optellum-partner-to-advance-ai-powered-lung-cancer-diagnosis/][https://optellum.com/2022/06/asco2022/]. The company is based in Oxford, UK, and operates as a commercial-stage medtech company [https://optellum.com/2022/06/optellums-uk-regulatory-certification-bolstered-by-ukca-marking/]. While specific founding year and company size are not explicitly stated on the provided snippets, the company's active news and regulatory updates, alongside partnerships and published studies, suggest a well-established and growing presence in the medical technology sector [https://optellum.com/2022/03/oxford-study-on-optellum-software-published-in-european-radiology/].

Optellum (optellum.com) specializes in providing AI-powered decision-support software aimed at the early diagnosis and optimal treatment for patients with lung diseases, particularly lung cancer [https://optellum.com/wp-content/uploads/2024/03/Optellum-Media-Pack-2024-1.0-3-FINAL.pdf]. Their core offering, the Optellum Virtual Nodule Clinic, is designed to manage incidental pulmonary nodules [https://optellum.com/incidental-management/]. This product is crucial as almost 2 million incidental pulmonary nodules are identified annually in the US, with a significant portion of patients not receiving proper follow-up [https://optellum.com/incidental-management/]. The Virtual Nodule Clinic helps healthcare providers increase the identification of these incidental nodules through automated processes [https://optellum.com/incidental-management/].

While specific pricing plans, tiers, or details on free versus paid features are not explicitly detailed on the accessible portions of Optellum's website, the company's focus is on providing a comprehensive, AI-enabled solution for healthcare systems. The Virtual Nodule Clinic has gained significant regulatory clearances, including CE certification and UKCA marking, underscoring its validated status as a medical device [https://optellum.com/2022/06/optellums-uk-regulatory-certification-bolstered-by-ukca-marking/]. Furthermore, Optellum holds FDA 510(k) clearance, solidifying its position as a leader in AI-enabled lung cancer diagnosis [https://optellum.com/wp-content/uploads/2024/03/Optellum-Media-Pack-2024-1.0-3-FINAL.pdf].

Optellum has established strategic partnerships to advance its technology, notably collaborating with GE Healthcare to address challenges in determining lung nodule malignancy [https://optellum.com/2022/06/asco2022/]. This partnership aims to enhance lung cancer diagnosis. The Virtual Nodule Clinic has been successfully implemented by leading institutions, such as the Vanderbilt Lung Institute, which was the first hospital in Tennessee to adopt the system and was involved in its clinical trials [https://optellum.com/2022/01/vanderbilt-lung-institute-implements-optellum-virtual-lung-nodule-clinic/]. An academic study published in European Radiology, originating from the University of Oxford and Oxford University Hospitals NHS Foundation Trust, also takes a closer look at the Optellum Lung Cancer Prediction (LCP) model, further validating its scientific underpinnings [https://optellum.com/2022/03/oxford-study-on-optellum-software-published-in-european-radiology/]. While no recent pricing changes are publicly available, these developments indicate a continuous investment in product development and market expansion.

Optellum (optellum.com) demonstrates a strategic hiring approach focused on expanding its core capabilities in Artificial Intelligence and lung cancer diagnosis. The company, dedicated to improving early diagnosis and treatment for lung disease patients [https://optellum.com/wp-content/uploads/2022/11/Data-team-job-ad-proposal_3.pdf], has recently sought talent to strengthen its technical and marketing teams.

Recent job postings indicate a clear push for growth in both data analysis and digital outreach.

Optellum advertised for an "Intern (Assistant Data Specialist, for medics)" [https://optellum.com/wp-content/uploads/2022/11/Data-team-job-ad-proposal_3.pdf], highlighting its commitment to leveraging data to enhance its AI-powered solutions. Additionally, the search for a "Part Time Digital Communications and Marketing Officer" [https://optellum.com/wp-content/uploads/2023/05/Part-Time-Digital-Communications-and-Marketing-Officer-JD.pdf] suggests a focus on increasing visibility and communicating the value of its Virtual Nodule Clinic and Lung Cancer Prediction AI platform to a wider audience.

These hiring patterns signal Optellum's strategic intent to not only advance its technological offerings but also to effectively market and scale its solutions within the healthcare sector. The company's ongoing collaborations, such as with GE Healthcare [https://optellum.com/2021/12/ge-optellum-partner-to-advance-ai-powered-lung-cancer-diagnosis/] and implementations like the Vanderbilt Lung Institute [https://optellum.com/2022/01/vanderbilt-lung-institute-implements-optellum-virtual-lung-nodule-clinic/], underscore a growth-oriented strategy that necessitates expanded teams. While specific layoff information is not available from the provided sources, the emphasis on new roles like data specialists and marketing officers points towards an expansion phase rather than retrenchment.

Optellum is a commercial-stage lung health company specializing in AI-powered decision-support software designed to facilitate early diagnosis and optimal treatment for patients with lung disease [https://optellum.com/wp-content/uploads/2024/03/Optellum-Media-Pack-2024-1.0-3-FINAL.pdf]. The company's core mission is to ensure that every patient receives diagnosis and treatment at the earliest possible stage, significantly improving health outcomes.

Optellum is recognized as a leader in AI-enabled lung cancer diagnosis, holding the distinction of being the first and only medtech company to achieve FDA 510(k) clearance and CE-M for such an application [https://optellum.com/wp-content/uploads/2024/03/Optellum-Media-Pack-2024-1.0-3-FINAL.pdf, https://optellum.com/2022/06/optellums-uk-regulatory-certification-bolstered-by-ukca-marking/].

While specific revenue figures for Optellum are not publicly detailed, the company's financial health is bolstered by strategic partnerships and consistent regulatory achievements. In early 2021, Optellum secured US FDA clearance, a significant milestone for an AI-assisted lung cancer diagnosis application [https://optellum.com/2022/06/optellums-uk-regulatory-certification-bolstered-by-ukca-marking/]. This was followed by UKCA marking, further strengthening its regulatory certification [https://optellum.com/2022/06/optellums-uk-regulatory-certification-bolstered-by-ukca-marking/]. These clearances underscore the market readiness and commercial potential of their Virtual Nodule Clinic and Lung Cancer Prediction AI solutions [https://optellum.com/incidental-management/].

Optellum has actively engaged in strategic collaborations to expand its reach and impact. Notably, the company partnered with GE Healthcare in December 2021 to advance AI-powered lung cancer diagnosis [https://optellum.com/2021/12/ge-optellum-partner-to-advance-ai-powered-lung-cancer-diagnosis/]. This partnership was highlighted at the 2022 ASCO Annual Meeting, where GE Healthcare showcased its collaborations aimed at advancing cancer care [https://optellum.com/2022/06/asco2022/]. Furthermore, Optellum's technology has been implemented in leading US hospitals, including the Vanderbilt Lung Institute, which became the first hospital in Tennessee to introduce the Optellum Virtual Lung Nodule Clinic in January 2022 [https://optellum.com/2022/01/vanderbilt-lung-institute-implements-optellum-virtual-lung-nodule-clinic/]. The company has also received support through funding from Innovate UK and the National Institute for Health Research (NIHR) in the UK, indicating robust backing for its innovative solutions [https://optellum.com/2022/06/optellums-uk-regulatory-certification-bolstered-by-ukca-marking/].

Optellum participates in significant industry events, demonstrating its commitment to advancing lung cancer diagnosis. In June 2022, Optellum attended the 2022 ASCO Annual Meeting in Chicago alongside its partners from GE Healthcare [https://optellum.com/2022/06/asco2022/]. This attendance highlights their active involvement in major medical conferences, where new technologies and strategic partnerships are often showcased to a broad audience of healthcare professionals and stakeholders.

Beyond just attending, Optellum has a history of engaging with prominent organizations and presenting their work. For example, in October 2016, the company received the EIT Health LUCINDA grant and subsequently presented at the EIT Health Summit [https://optellum.com/wp-content/uploads/2024/03/Optellum-Media-Pack-2024-1.0-3-FINAL.pdf]. Such participations are crucial for Optellum to share its advancements, collaborate with other innovators, and secure funding that supports its mission to improve lung cancer outcomes.

These event participations, whether as attendees, presenters, or grant recipients, underscore Optellum's dedication to fostering innovation and collaboration within the healthcare ecosystem. By actively engaging with the medical and technological communities, Optellum not only promotes its Virtual Nodule Clinic software but also contributes to the broader conversation around early lung cancer diagnosis and treatment [https://optellum.com/incidental-management/].